Compare Cigna Corp (CI) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Incyte Corporation — how do they compare? Cigna Corp trades at $273 (market cap $73.56B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Cigna Corp is far larger — about 3× Incyte Corporation's market cap, and Cigna Corp pays a 2.24% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CI | INCY | |
|---|---|---|
Market Cap | $73.56B | $24.54B |
Sector | Health | Health |
52-Week High | $311.00 | $129.93 |
52-Week Low | $244.41 | $81.61 |
Enterprise Value | $98.27B | $20.04B |
Dividend Yield | 2.24% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
